Industry: Medicinal and Botanical Manufacturing
Tilray is a Canadian pharmaceutical and cannabis company, incorporated in the United States with primary operations headquartered in Toronto, Ontario. Tilray also has operations in Australia, New Zealand, Germany, Portugal, and Latin America. Tilray was founded in 2013. It was originally incorporated under the umbrella of Seattle-based Privateer Holdings. Tilray became the first medical cannabis producer in North America to be GMP certified in December 2016. In July 2018, the company became the first cannabis company to IPO on the NASDAQ and trades under the ticker symbol TLRY. In September 2018, Tilray became the first Canadian cannabis company to legally export medical cannabis to the U.S. for a clinical trial. In December 2018, the company signed a deal with Novartis subsidiary Sandoz to sell, distribute and co-brand Tilray's non-smokeable/non-combustible medical cannabis products in legal markets worldwide. On June 19, 2018, Tilray announced the launch of High Park Company which would operate in the adult recreational cannabis market to establish unique adult-use brands in Canada upon its legalization.
Market Cap: US$ 1.1B
PE Ratio: -2.4
Dividend Yield: 0.0%
Last Earnings Date: Aug. 10, 2020
Jun 15, 2020Tweet
Apr 23, 2020Tweet